Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Top twenty single nucleotide polymorphism (SNPs) in postmenopausal current estrogen-only users (N = 78) that showed the strongest heterogeneity between never hormone therapy users and estrogen-only users.

From: Polymorphisms in hormone metabolism and growth factor genes and mammographic density in Norwegian postmenopausal hormone therapy users and non-users

Gene SNP SNPs per gene Alleles WW WV+VV Beta1 SE P1 Pb2 Pint3
PPARG rs1175543 32 A/G 42 36 -9.80 3.00 0.0017 0.0535 0.0028
CYP1B1 rs4670813 17 G/A 25 53 -9.99 3.17 0.0023 0.0396 0.0059
CYP1B1 rs162550 17 G/C 44 34 8.19 3.11 0.0103 0.1753 0.0068
ESR2 rs1256063 29 G/A 65 13 12.27 4.00 0.0030 0.0868 0.0069
IGFBP1/IGFBP3 rs1496497 29 G/A 47 31 -8.08 3.13 0.0119 0.3464 0.0155
IL6 rs6949149 19 G/T 70 8 -12.82 4.97 0.0119 0.2256 0.0206
TGFB1 rs8179181 11 A/T 48 30 7.91 3.16 0.0144 0.1579 0.0214
ESR1 rs2295190 12 G/T 51 27 -6.45 3.36 0.0590 0.7086 0.0293
PPARG rs1151996 32 A/C 36 42 -7.18 3.11 0.0236 0.7554 0.0520
CYP1B1 rs1625 17 T/G 49 29 6.74 3.25 0.0418 0.7098 0.0557
TGFB1 rs1982072 11 A/T 35 43 -6.32 3.17 0.0498 0.5478 0.0577
CYP1A1/CYP1A2 rs11072507 13 C/G 39 39 7.26 3.24 0.0281 0.3656 0.0578
CYP1B1 rs162557 17 G/A 47 31 6.05 3.21 0.0635 1.0791 0.0622
IGFBP1/IGFBP3 rs10241749 29 A/G 49 29 7.10 3.35 0.0375 1.0878 0.0657
PPARG rs2120825 32 T/G 56 22 8.12 3.42 0.0201 0.6421 0.0733
COMT rs12627876 29 C/T 77 1 26.61 13.83 0.0582 1.6881 0.0827
CYP1A1/CYP1A2 rs2606345 13 A/C 38 40 7.00 3.09 0.0263 0.3415 0.0886
IGFBP1/IGFBP3 rs4619 29 A/G 28 50 -6.51 3.31 0.0531 1.5400 0.0950
HSD3B1/HSD3B2 rs6428828 3 A/T 38 40 5.77 3.08 0.0650 0.1951 0.0954
PRL rs1123886 34 T/C 36 42 6.22 3.17 0.0533 1.8109 0.2058
  1. 1From linear regression models using percent mammographic density as the outcome variable. Adjusted for age and BMI in a dominant model of inheritance. See Table S2 in Additional file 2 for the stratum-specific results in never HT users. 2Bonferroni-adjusted P values. 3P for interaction for ET vs. never HT users in all postmenopausal women (N = 2,036).